Under the new agreement, effective December 1, Lantheus with provide its Definity ultrasound contrast agent to Premier's 1,600-plus hospitals and healthcare sites in the U.S.
The pact is the second consecutive sole-source Definity agreement that Premier has awarded to Lantheus.
Related Reading
Lantheus to license Bracco's CardioGen PET tracer, September 24, 2008
Definity echo contrast agent lands on FDA drug safety list, September 8, 2008
IBA, Lantheus ink radiopharma deal, July 31, 2008
Lantheus reports data from cardiac PET trial, June 17, 2008
Bracco, Novation ink supply deal, September 3, 2008
Copyright © 2008 AuntMinnie.com
